Mohammad-Ali Jenabian
Mohammad-Ali Jenabian
Professeur
Domaines d'expertise
Cheminement académique
Depuis Juin 2023: Professeur Titulaire, Immunologie et Virologie, Département des Sciences Biologiques, UQAM, Montréal, Québec, Canada.
2018 - 2023: Professeur Agregé, Immunologie et Virologie, Département des Sciences Biologiques, UQAM, Montréal, Québec, Canada.
2014-2018: Professeur Adjoint, Immunologie et Virologie, Département des Sciences Biologiques, UQAM, Montréal, Québec, Canada.
2011-2014: Chercheur Postdoctoral, Immunologie Clinique, Institut de recherche du Centre universitaire de santé McGill, Université McGill, Montréal, Québec, Canada.
2009-2011: Chercheur Postdoctoral, Immunologie Fondamentale, Institut Mondor de Recherche Biomédicale (INSERM U955), Université Paris-Est Créteil (Paris XII), Paris, France.
2009: Docteur ès Sciences (Ph.D.), Virologie, Centre de Recherche Biomédicale des Cordeliers (INSERM U743) et Hôpital Européen Georges-Pompidou, Université Pierre et Marie Curie (Paris VI), Paris, France.
2003: Docteur ès Médicine Vétérinaire (D.V.M.), Faculté de Médicine Vétérinaire, Université de Karaj, Karaj, Iran.
Projets de recherche et/ou de recherche-création en cours
Partenaires (organismes, entreprises)
- Membre du comité exécutif, Réseau Sida et Maladies Infectieuses, Le Fonds de recherche du Québec - Santé (FRQ-S)
- Membre régulier, Réseau de Thérapie Cellulaire et Tissulaire, (ThéCell), Le Fonds de recherche du Québec - Santé (FRQ-S)
- Membre régulier, Réseau Canadien pour les essais VIH des IRSCs (CTN)
- Co-chercheur, Consortium canadien de recherche sur la guérison du VIH (CanCURE)
- Membre régulier, Réseau intersectoriel de recherche en santé de l'Université du Québec(RISUQ)
- Membre régulier, Centre d'Excellence en Recherche sur les Maladies Orphelines - Fondation Courtois (CERMO-FC)
Affiliations externes principales
- Sujets choisis en biochimie de la sante (2025, 2024, 2023, 2022, 2021, 2020)
- Spécialisation en biologie cellulaire (5 cr.) (2025, 2024, 2023)
- Immunologie (4 cr.) (2024, 2023, 2022)
- Immunologie (2023)
- Mecanismes de defense (4 cr) (2021)
- Diversite des microorganismes (3 credits) (2019)
- Membre élu, Collège de nouveaux chercheurs et créateurs en arts et en science de la Société royale du Canada (SRC), 2024
- Prix d'excellence en recherche, Association canadienne de recherche sur le VIH et Fondation canadienne de recherche sur le sida, 2022
- Prix de voyage (competitif), Instituts de recherche en santé du Canada (IRSC), Conférence AIDS 2022.
- Prix d'excellence de la relève de l'Université du Québec, lauréat de l'UQAM, volet Sciences naturelles, génie et sciences de la santé, 2018
- Prix d'excellence de la recherche - Volet Professeurs - Relève, Faculté des sciences, UQAM, 2017.
- Chaire de recherche du Canada en Immuno-Virologie (renouvelée, 2016-2027).
- Bourse salariale de nouveau chercheur, Instituts de recherche en santé du Canada (IRSC), 2016.
- Chercheur-Boursier junior 1, Fonds de recherche du Québec - Santé (FRQ-S), 2016.
- Prix de la Société Internationale du Sida (IAS), Symposium sur le Cancer et VIH, Paris, France, 2017
- Prix de la Société Internationale du Sida (IAS), Symposium sur l'éradication du VIH, Vancouver, BC, Canada, 2015.
- Bourse postdoctorale, Instituts de recherche en santé du Canada (IRSC) / Réseau canadien pour les essais VIH (CTN), 2012-2014.
- Prix de meilleure présentation orale, Symposium international sur le VIH et les maladies infectieuses émergentes (ISHEID), Marseille, France, 2014.
- Prix du nouveau chercheur, 20ème conférence sur les rétrovirus et les infections opportunistes (CROI), Atlanta, GA, États-Unis, 2013.
- Bourse de voyage, Réseau de thérapie cellulaire et tissulaire du FRQ-S, 2013.
- Prix internationale, Conférence mondiale sur le sida, Washington DC, USA, 2012.
- Prix du nouveau chercheur, 19ème conférence sur les rétrovirus et les infections opportunistes (CROI), Seattle, WA, États-Unis, 2012.
- Délégué universitaire de l'UQAM aux instituts de recherche en santé du Canada (IRSCs)
- Membre, Comité institutionnel de protection des animaux (CIPA)
- Membre, Comité stratégique de la recherche, Département des sciences biologiques
Directions de thèses et mémoires
- Yero Diaz, Alexis. (2022). Impact of early antiretroviral therapy initiation and immunotherapy interventions on the dynamics of regulatory T cells during SIV-HIV infections. (Thèse de doctorat). Université du Québec à Montréal.
- Swaminathan, Sharada. (2019). Development of thymic regulatory T cells during human immunodeficiency virus (HIV) infection. (Mémoire de maîtrise). Université du Québec à Montréal.
Publications
- Iannello, A., Samarani, S., Allam, O., et al. (2017). A potentially protective role of IL-18 Binding Protein in HIV-infected Long-Term Non-Progressors. Cytokine, 90, 96–99. http://dx.doi.org/10.1016/j.cyto.2016.10.018.
- Allam, O., Samarani, S., Jenabian, M.-A., et al. (2017). Differential synthesis and release of IL-18 and IL-18 Binding Protein from human platelets and their implications for HIV infection. Cytokine, 90, 144–154. http://dx.doi.org/10.1016/j.cyto.2016.10.016.
- Mossoro-Kpinde, C.D., Mboumba Bouassa, R.-S., Jenabian, M.-A., et al. (2016). Analytical Performances of Human Immunodeficiency Virus Type 1 RNA-Based Amplix® Real-Time PCR Platform for HIV-1 RNA Quantification. AIDS Research and Treatment, 2016, Article ID 7954810. http://dx.doi.org/10.1155/2016/7954810.
- Huang, Y., Hoque, M.T., Jenabian, M.-A., et al. (2016). Antiretroviral drug transporters and metabolic enzymes in human testicular tissue: potential contribution to HIV-1 sanctuary site. Journal of Antimicrobial Chemotherapy, 71(7), 1954–1965. http://dx.doi.org/10.1093/jac/dkw046.
- Ahmad, A., Mehraj, V., Jenabian, M.-A., Samarani, S., Tremblay, C. et Routy, J.-P. (2016). Combination antiretroviral therapy and indoleamine 2,3-dioxygenase in HIV infections: challenges and new opportunities. AIDS, 30(11), 1839–1841. http://dx.doi.org/10.1097/QAD.0000000000001168.
- Aounallah, M., Dagenais-Lussier, X., El-Far, M., et al. (2016). Current topics in HIV pathogenesis, part 2: Inflammation drives a Warburg-like effect on the metabolism of HIV-infected subjects. Cytokine & Growth Factor Reviews, 28, 1–10. http://dx.doi.org/10.1016/j.cytogfr.2016.01.001.
- Mossoro-Kpinde, C.D., Jenabian, M.-A., Gody, J.C., et al. (2016). Evaluation of the Upgraded Version 2.0 of the Roche COBAS® AmpliPrep/COBAS® TaqMan HIV-1 Qualitative Assay in Central African Children. Open AIDS Journal, 10, 158–163. http://dx.doi.org/10.2174/1874613601610010158.
- Samarani, S., Allam, O., Sagala, P., et al. (2016). Imbalanced production of IL-18 and its antagonist in human diseases, and its implications for HIV-1 infection. Cytokine, 82, 38–51. http://dx.doi.org/10.1016/j.cyto.2016.01.006.
- Jenabian, M.-A., Costiniuk, C.T., Mehraj, V., et al. (2016). Immune tolerance properties of the testicular tissue as a viral sanctuary site in ART-treated HIV-infected adults. AIDS, 30(18), 2777–2786. http://dx.doi.org/10.1097/QAD.0000000000001282.
- Jenabian, M.-A., Mehraj, V., Costiniuk, C.T., et al. (2016). Influence of Hepatitis C Virus Sustained Virological Response on Immunosuppressive Tryptophan Catabolism in ART-Treated HIV/HCV Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes, 71(3), 254–262. http://dx.doi.org/10.1097/QAI.0000000000000859.
- Wacleche, V.S., Goulet, J.-P., Gosselin, A., et al. (2016). New insights into the heterogeneity of Th17 subsets contributing to HIV-1 persistence during antiretroviral therapy. Retrovirology, 13(59). http://dx.doi.org/10.1186/s12977-016-0293-6.
- Mehraj, V., Jenabian, M.-A., Ponte, R., et al. (2016). The plasma levels of soluble ST2 as a marker of gut mucosal damage in early HIV infection. AIDS, 30(10), 1617–1627. http://dx.doi.org/10.1097/QAD.0000000000001105.
- Routy, J.-P., Angel, J., Patel, M., et al. (2015). Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy. HIV Medicine, 16(1), 48–56. http://dx.doi.org/10.1111/hiv.12171.
- Routy, J.-P., Mehraj, V., Vyboh, K., Cao, W., Kema, I. et Jenabian, M.-A. (2015). Clinical Relevance of Kynurenine Pathway in HIV/AIDS: An Immune Checkpoint at the Crossroads of Metabolism and Inflammation. AIDS Reviews, 17(2), 96–106. http://www.aidsreviews.com/files/2015_17_2_096-106.pdf.
- Hubert, A., Subra, C., Jenabian, M.-A., et al. (2015). Elevated Abundance, Size, and MicroRNA Content of Plasma Extracellular Vesicles in Viremic HIV-1+ Patients: Correlations With Known Markers of Disease Progression. Journal of Acquired Immune Deficiency Syndromes, 70(3), 219–227. http://dx.doi.org/10.1097/QAI.0000000000000756.
- Vyboh, K., Jenabian, M.-A., Mehraj, V. et Routy, J.-P. (2015). HIV and the gut microbiota, partners in crime: breaking the vicious cycle to unearth new therapeutic targets. Journal of Immunology Research, 2015, Article ID 614127. http://dx.doi.org/10.1155/2015/614127.
- Costiniuk, C.T. et Jenabian, M.-A. (2015). HIV reservoir dynamics in the face of highly active antiretroviral therapy. AIDS Patient Care and STDs, 29(2), 55–68. http://dx.doi.org/10.1089/apc.2014.0173.
- Cleret-Buhot, A., Zhang, Y., Planas, D., et al. (2015). Identification of novel HIV-1 dependency factors in primary CCR4(+)CCR6(+)Th17 cells via a genome-wide transcriptional approach. Retrovirology, 12(102). http://dx.doi.org/10.1186/s12977-015-0226-9.
- Jenabian, M.-A., El-Far, M., Vyboh, K., et al. (2015). Immunosuppressive Tryptophan Catabolism and Gut Mucosal Dysfunction Following Early HIV Infection. The Journal of Infectious Diseases, 212(3), 355–366. http://dx.doi.org/10.1093/infdis/jiv037.
- DaFonseca, S., Niessl, J., Pouvreau, S., et al. (2015). Impaired Th17 polarization of phenotypically naive CD4(+) T-cells during chronic HIV-1 infection and potential restoration with early ART. Retrovirology, 12(38). http://dx.doi.org/10.1186/s12977-015-0164-6.
- Jenabian, M.-A., Talla, F., Talla, P., et al. (2015). Pitfalls of antiretroviral drug resistance genotyping of HIV-1 Group M and Group N from Cameroon by sequenced-based assays. Nigerian Medical Journal, 56(6), 420–424. http://dx.doi.org/10.4103/0300-1652.171613.
- Trottier, B., Galanakis, C., Longpré, D., et al. (2015). Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054). HIV Clinical Trials, 16(3), 111–116. http://dx.doi.org/10.1179/1528433614Z.0000000015.
- Jenabian, M.-A., Costiniuk, C.T., Mboumba Bouassa, R.S., Chapdeleine Mekue Mouafo, L., Brogan, T.V. et Bélec, L. (2015). Tackling virological failure in HIV-infected children living in Africa. Expert Review of Anti-infective Therapy, 13(10), 1213–1223. http://dx.doi.org/10.1586/14787210.2015.1068117.
- LeGoff, J., Roques, P., Jenabian, M.-A., et al. (2015). Variability of human immunodeficiency virus-1 in the female genital reservoir during genital reactivation of herpes simplex virus type 2. Clinical Microbiology and Infection, 21(9), 873.e1–873.e9. http://dx.doi.org/10.1016/j.cmi.2015.05.014.
- Costiniuk, C.T. et Jenabian, M.-A. (2014). Cell-to-cell transfer of HIV infection: implications for HIV viral persistence. The Journal of General Virology, 95(Pt 11), 2346–2355. http://dx.doi.org/10.1099/vir.0.069641-0.
- Carriere, M., Lacabaratz, C., Kok, A., et al. (2014). HIV "elite controllers" are characterized by a high frequency of memory CD8+ CD73+ T cells involved in the antigen-specific CD8+ T-cell response. The Journal of Infectious Diseases, 209(9), 1321–1330. http://dx.doi.org/10.1093/infdis/jit643.
- Mehraj, V., Jenabian, M.-A., Vyboh, K. et Routy, J.-P. (2014). Immune Suppression by Myeloid Cells in HIV Infection: New Targets for Immunotherapy. Open AIDS Journal, 8, 66–78. http://dx.doi.org/10.2174/1874613601408010066.
- Costiniuk, C.T., Sigal, A., Jenabian, M.-A., Nijs, P. et Wilson, D. (2014). Short communication: Lower baseline CD4 count is associated with a greater propensity toward virological failure in a cohort of South African HIV patients. AIDS Research and Human Retroviruses, 30(6), 531–534. http://dx.doi.org/10.1089/AID.2014.0011.
- Jenabian, M.-A., Patel, M., Kema, I., et al. (2014). Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection. Clinical and Experimental Immunology, 178(1), 102–111. http://dx.doi.org/10.1111/cei.12396.
- Costiniuk, C.T. et Jenabian, M.-A. (2014). The lungs as anatomical reservoirs of HIV infection. Reviews in Medical Virology, 24(1), 35–54. http://dx.doi.org/10.1002/rmv.1772.
- Lebouché, B., Jenabian, M.-A., Singer, J., et al. (2014). The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy – CTN PT006: study protocol for a randomized controlled trial. Trials, 15(390). http://dx.doi.org/10.1186/1745-6215-15-390.
- Moussa, S., Jenabian, M.-A., Gody, J.C., et al. (2013). Adaptive HIV-specific B cell-derived humoral immune defenses of the intestinal mucosa in children exposed to HIV via breast-feeding. PLoS One, 8(5). http://dx.doi.org/10.1371/journal.pone.0063408.
- Jenabian, M.-A., Patel, M., Kema, I., et al. (2013). Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers. PLoS One, 8(10). http://dx.doi.org/10.1371/journal.pone.0078146.
- Koyalta, D., Jenabian, M.-A., Djouater, B., et al. (2013). Field evaluation in Chad of community usage of CD4 T lymphocyte counting by alternative single-platform flow cytometry. BMC Health Services Research, 13(373). http://dx.doi.org/10.1186/1472-6963-13-373.
- Jenabian, M.-A., Nicolette, C.A., Tcherepanova, I.Y., Debenedette, M.A., Gilmore, N. et Routy, J.-P. (2013). Impact of autologous dendritic cell-based immunotherapy (AGS-004) on B- and T-cell subset changes and immune activation in HIV-infected patients receiving antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 64(4), 345–350. http://dx.doi.org/10.1097/QAI.0b013e3182a4b9ad.
- Jenabian, M.-A., Seddiki, N., Yatim, A., et al. (2013). Regulatory T cells negatively affect IL-2 production of effector T cells through CD39/adenosine pathway in HIV infection. PLoS Pathogens, 9(4). http://dx.doi.org/10.1371/journal.ppat.1003319.
- Koyalta, D., Jenabian, M.-A., Nadjiouroum, N., et al. (2013). Single-platform, volumetric, CD45-assisted pan-leucogating flow cytometry for CD4 T lymphocytes monitoring of HIV infection according to the WHO recommendations for resource-constrained settings. BMC Research Notes, 6(169). http://dx.doi.org/10.1186/1756-0500-6-169.
- Bernier, A., Cleret-Buhot, A., Zhang, Y., et al. (2013). Transcriptional profiling reveals molecular signatures associated with HIV permissiveness in Th1Th17 cells and identifies peroxisome proliferator-activated receptor gamma as an intrinsic negative regulator of viral replication. Retrovirology, 10(160). http://dx.doi.org/10.1186/1742-4690-10-160.
- Jenabian, M.-A., Ancuta, P., Gilmore, N. et Routy, J.-P. (2012). Regulatory T cells in HIV infection: can immunotherapy regulate the regulator? Clinical and Developmental Immunology, 2012, Article ID 908314. http://dx.doi.org/10.1155/2012/908314.
- Saidi, H., Jenabian, M.-A. et Belec, L. (2012). Understanding factors that modulate HIV infection at the female genital tract mucosae for the rationale design of microbicides. AIDS Research and Human Retroviruses, 28(11), 1485–1497. http://dx.doi.org/10.1089/AID.2012.0049.
- Nikolova, M., Carriere, M., Jenabian, M.-A., et al. (2011). CD39/adenosine pathway is involved in AIDS progression. PLoS Pathogens, 7(7). http://dx.doi.org/10.1371/journal.ppat.1002110.
- Belec, L., Jenabian, M.-A., Charpentier, C. et Saidi, H. (2011). Combinatorial prevention of HIV transmission in women: the case for a vaginal microbicide. Future Microbiology, 6(7), 731–737. http://dx.doi.org/10.2217/fmb.11.64.
- Charpentier, C., Koyalta, D., Ndinaromtan, M., et al. (2011). Distribution of HIV-1 and HSV-2 epidemics in Chad revealing HSV-2 hot-spot in regions of high-risk HIV spread. Journal of Infection in Developing Countries, 5(1), 64–67. http://dx.doi.org/10.3855/jidc.1054.
- Charpentier, C., Jenabian, M.-A., Piketty, C., et al. (2011). Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy. Scandinavian Journal of Infectious Diseases, 43(5), 373–379. http://dx.doi.org/10.3109/00365548.2011.552520.
- Auvert, B., Jenabian, M.-A., Saidi, H., Lissouba, P. et Belec, L. (2011). Partial inactivation of CCR5- and CXCR4- tropic HIV-1 by human urine. Archives of Virology, 156(12), 2181–2186. http://dx.doi.org/10.1007/s00705-011-1114-9.
- Jenabian, M.-A., Saidi, H., Charpentier, C., et al. (2010). Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization. AIDS Research and Therapy, 7(16). http://dx.doi.org/10.1186/1742-6405-7-16.
- Jenabian, M.-A., Auvert, B., Saidi, H., Lissouba, P., Matta, M. et Belec, L. (2010). Potent in vitro inactivation of both free and cell-associated CCR5- and CXCR4-tropic HIV-1 by common commercial soap bars from South Africa. Journal of Acquired Immune Deficiency Syndromes, 54(4), 340–342. http://dx.doi.org/10.1097/QAI.0b013e3181e3dbf6.
- Metlas, R.M., Srdic, T.V., Jenabian, M.-A., et al. (2009). Immunoglobulin G-reactive antibodies from sera of healthy individuals enriched in IgG2--therapeutic potential in HIV-1 infection. Current HIV Research, 7(4), 378–383. http://dx.doi.org/10.2174/157016209788680516.
- Jenabian, M.-A., Saidi, H., Charpentier, C., et al. (2009). In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20). The Journal of Antimicrobial Chemotherapy, 64(6), 1192–1195. http://dx.doi.org/10.1093/jac/dkp380.
- Eslahpazir, J., Jenabian, M.-A., Bouhlal, H., et al. (2008). Infection of macrophages and dendritic cells with primary R5-tropic human immunodeficiency virus type 1 inhibited by natural polyreactive anti-CCR5 antibodies purified from cervicovaginal secretions. Clinical and Vaccine Immunology (CVI), 15(5), 872–884. http://dx.doi.org/10.1128/CVI.00463-07.
- Saidi, H., Jenabian, M.-A., Gombert, B., Charpentier, C., Mannarini, A. et Belec, L. (2008). Pre-clinical development as microbicide of zinc tetra-ascorbo-camphorate, a novel terpenoid derivative: potent in vitro inhibitory activity against both R5- and. AIDS Research and Therapy, 5(10). http://dx.doi.org/10.1186/1742-6405-5-10.
- Saidi, H., Nasreddine, N., Jenabian, M.-A., et al. (2007). Differential in vitro inhibitory activity against HIV-1 of alpha-(1-3)- and alpha-(1-6)-D-mannose specific plant lectins: implication for microbicide development. Journal of Translational Medicine, 5(28). http://dx.doi.org/10.1186/1479-5876-5-28.